SEC Form 4 · accession 0001193125-26-355707
Korsana Biosciences, Inc. · KRSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Regina Margaret Graul
Officer — See Remarks · Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 18, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001755237
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par value | Aug 14, 2026 | M | 55,849 | $3.30 | A | 156,152 | D | |
| Common Stock, no par value | Aug 14, 2026 | F | 48,629 | $3.79 | D | 107,523 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF1 | $3.30 | Aug 14, 2026 | M | 55,849 | D | — | Aug 3, 2034 | Common Stock | 55,849 | 0 | D |
Explanation of responses
- F1The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.
- F2The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price.
Remarks
President and Chief Executive Officer